New Survey Reveals Real World Impact of Medical Device Tax

Posted on Tue/18/FebruaryTue/18/February by AZBio

Results Show Substantial Job Loss, Reduction in R&DContinue reading→

Industry leaders reach out to CMS on proposed changes to Medicare Part D

Posted on Tue/18/FebruarySun/23/February by AZBio

Organizations reflecting a wide breadth of companies and organizations representing, among others, multiple healthcare sectors, employers and patients share concerns over the proposed Medicare Part D changes with CMS Administrator.Continue reading→

UA Study on Flu Evolution May Change Textbooks, History Books

Posted on Tue/18/FebruaryTue/18/February by AZBio

A new study reconstructing the evolutionary tree of flu viruses challenges conventional wisdom and solves some of the mysteries surrounding flu outbreaks of historical significance

By Daniel Stolte, University Communcations, University Communications | February 14, 2014 Continue reading→

Of mice and men: fine-tuning salmonella-based vaccines

Posted on Mon/17/FebruarySun/23/February by AZBio

An innovative vaccine technology makes use of reengineered salmonella to deliver protective immunity. If such recombinant attenuated salmonella vaccines, or RASVs, can be perfected, they hold the promise of safe, low-cost, orally-administered defenses against viral, bacterial, fungal and parasitic infections.Continue reading→

UA scientist pushes new uses for DNA tests

Posted on Mon/17/FebruaryMon/17/February by AZBio

Frederick Zenhausern, a former nanobioscience researcher at the University of Arizona, is starting a company to develop a DNA test to catch criminals.

By Angela M. Gonzales, Phoenix Business Journal Continue reading→

TGen Physician-In-Chief Dr. Daniel Von Hoff inducted today into exclusive Joshua Lederberg Society

Posted on Fri/14/FebruaryFri/14/February by AZBio

Dr. Von Hoff is honored for advancing FDA approved treatment benefiting pancreatic cancer patientsContinue reading→

Tucson To Host Globally Recognized Cancer Research Conference Feb. 25 And 26

Posted on Fri/14/FebruaryFri/14/February by AZBio

The world’s top scientific minds will convene at Tucson’s Hilton El Conquistador Resort February 25 and 26 to collaborate and share leading-edge developments in cancer diagnostics and treatment. The 10th Annual Tucson Symposium puts Tucson at the leading edge of cancer research, diagnostics and treatment, and promises to further the field of personalized medicine and positively impact medical practice all over the world. (PR Newswire: TUCSON, Ariz., Feb. 13, 2014 )Continue reading→

UA Regents’ Professor Elected to National Academy of Engineering

Posted on Fri/14/FebruaryFri/14/February by AZBio

Harrison Barrett, a UA Regents’ Professor who has made groundbreaking advances in medical imaging, has been elected as a member of the National Academy of Engineering.Continue reading→

TGen and Mayo Clinic researchers use genomic sequencing to help identify new therapies for bile duct cancer

Posted on Fri/14/FebruaryFri/14/February by AZBio

Study targets EGFR and FGFR cellular pathways to treat rare diseaseContinue reading→

NCI SBIR Direct to Phase II Pilot Program

Posted on Thu/13/FebruaryThu/13/February by AZBio

Direct to Phase II Pilot Program is here!
Jump Into New Funding Opportunities Now

Finding funding to continue your innovative cancer research can be difficult. Luckily, there’s some good news.

The National Cancer Institute Small Business Innovation Research (NCI SBIR) Development Center is implementing the SBIR Direct to Phase II Pilot solicitation, PAR-14-088, per the 2011 SBIR & STTR Reauthorization Act, allowing applicants that have demonstrated the R&D and technical merit characteristic of a Phase I (R43) SBIR project to bypass Phase I and apply directly for SBIR Phase II grants.

We encourage you to review the opportunity below and consider applying.

Direct Phase II Pilot Program

The NCI SBIR Development Center welcomes qualified applicants to participate in the newly authorized Direct-to-Phase II SBIR grant mechanism. This program applies to SBIR only, NOT STTR.This program is designed to expand opportunities for small business concerns and accelerate the pace of technology development and commercialization. Applicants that have demonstrated the R&D and technical merit characteristic of a Phase 1 (R43) SBIR project are encouraged to apply.

Standard deadlines apply. The next application receipt date is April 5, 2014, 5:00PM local time.

NIH SBIR and STTR applicants may now switch programs at Phase II or Phase IIB

Applicants may now switch between SBIR & STTR Programs. Those who previously were funded under an STTR Phase I award are now eligible to apply for an SBIR Phase II award and vice versa.

Those who previously were funded under an STTR Phase II award are now eligible to apply for an SBIR Phase IIB award and vice versa.

Small business concerns that are majority-owned by multiple venture capital operating companies (VCOCS), hedge funds, and/or private equity firms are eligible to apply to the NIH SBIR program. View frequently asked questions on VC participation.

View the Application Guide for NIH and Other PHS Agencies for more information on preparing and submitting SBIR & STTR applications.

Recently ReleasedThe SBIR Phase IIB Bridge Award RFA is now live. Please apply by April 21, 2014, 5:00PM local time.

How to Apply
For resources and examples of SBIR grant applications and contract proposals, please visit http://sbir.cancer.gov/resource/apply/.

Please visit http://sbir.cancer.gov/ to learn more about the NCI SBIR & STTR Programs.

The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.